PHILIP ELANGWE: Open Payments
NPI 1780776435 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$984 in 51 payments from 17 companies in 2025. Trend: 2023 $1,750 · 2024 $1,453 · 2025 $984
Food & beverage: $984
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $285 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $155 |
| ABBVIE INC. | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| GlaxoSmithKline, LLC. | 4 | $62 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Aimmune Therapeutics, Inc. | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
| Inspire Medical Systems, Inc. | 1 | $25 |
Products named: BREZTRI, CAPLYTA, REXULTI, FARXIGA, Kerendia, VRAYLAR, TRELEGY ELLIPTA, AIRSUPRA.
Industry payments across AR — which companies pay providers there.
